Integrated single-cell transcriptomics reveals miR-941 targets CLDN4 to inhibit malignant progression of thyroid cancer through the PI3K/AKT signaling pathway.
- 1Department of Thyroid Surgery The Tenth Affiliated Hospital Southern Medical University (Dongguan People's Hospital) Dongguan Guangdong China.
- 2Northern Jiangsu People's Hospital Affiliated to Yangzhou University Jiangsu China.
- 3The Fourth General Surgery Department of the Fourth Affiliated Hospital of China Medical University Shenyang China.
Abstract
Claudin-4 (CLDN4), a key tight junction protein, has been implicated in tumor progression; however, its functional role and regulatory mechanisms in thyroid cancer remain unclear. This study aimed to investigate the contribution of CLDN4 to malignant progression and its interaction with the tumor-immune microenvironment. Single-cell and bulk transcriptomic data were integrated to identify CLDN4-associated malignant epithelial subpopulations. CLDN4 expression was validated in 25 paired papillary thyroid carcinoma (PTC) tissues by qRT-PCR, western blotting, and immunohistochemistry. Functional assays were performed using CLDN4-overexpressing and CLDN4-knockdown B-CPAP and TPC-1 cells. The miR-941-CLDN4 interaction was verified by luciferase reporter assays. PI3K/AKT signaling and macrophage polarization were evaluated in vitro, and tumor growth was assessed in a xenograft mouse model. A CLDN4-high epithelial subpopulation was identified and associated with advanced tumor stage and PI3K/AKT activation. CLDN4 was upregulated in PTC tissues, whereas miR-941 was downregulated. High CLDN4 expression correlated with larger tumor size, lymphatic metastasis, and vascular migration. CLDN4 overexpression promoted proliferation, migration, colony formation, and apoptosis resistance, whereas knockdown produced the opposite effects. miR-941 directly targeted CLDN4 and attenuated its oncogenic effects. CLDN4 activated PI3K/AKT signaling, while PI3K inhibition reversed these phenotypes. CLDN4 also promoted M2 macrophage polarization and suppressed M1 polarization. In vivo, CLDN4 enhanced tumor growth, which was inhibited by PI3K blockade. miR-941 suppresses CLDN4 to inhibit PTC progression through modulation of the PI3K/AKT pathway. These findings provide mechanistic insights into tumor progression and immune microenvironment remodeling, highlighting CLDN4 as a potential therapeutic target.
Related
- Integrated transcriptomics reveals a TNFRSF-metabolism axis and a context-dependent BCMA signaling state in myeloma progression.
- Integrated Single-Cell and Spatial Transcriptomics Reveal Convergence on a Senescence-Associated B Cell-MIF Signaling Axis in Joint Aging and Osteoarthritis Progression.
- A single-cell transcriptomics-based prognostic model identifies TM4SF1 as a key promoter of malignant progression in lung adenocarcinoma
- Filamin A Promotes Malignant Progression and Poor Prognosis in Glioma by Regulating EMT-Related Signaling Pathways.
- Integrated transcriptomics identifies key genes and pathways driving CKD to ESRD progression: implications for diagnosis and prognosis
BibTeX
@article{zhou2026integrated,
title = {{Integrated single-cell transcriptomics reveals miR-941 targets CLDN4 to inhibit malignant progression of thyroid cancer through the PI3K/AKT signaling pathway.}},
author = {Jinghua Zhou and Tiancheng Fu and Guoxiang Huang and Guangfeng Luo and Chengcheng Wang and Yanze Wang and Ziyang Ding and Xiarong Hu and Yudong Li and Zhen Li},
journal = {Journal of cell communication and signaling},
year = {2026},
month = oct,
doi = {10.1002/ccs3.70123},
url = {https://europepmc.org/article/MED/42953376},
note = {CC BY},
}
RIS
TY - JOUR
TI - Integrated single-cell transcriptomics reveals miR-941 targets CLDN4 to inhibit malignant progression of thyroid cancer through the PI3K/AKT signaling pathway.
AU - Jinghua Zhou
AU - Tiancheng Fu
AU - Guoxiang Huang
AU - Guangfeng Luo
AU - Chengcheng Wang
AU - Yanze Wang
AU - Ziyang Ding
AU - Xiarong Hu
AU - Yudong Li
AU - Zhen Li
PY - 2026
DA - 2026/10/27
JO - Journal of cell communication and signaling
DO - 10.1002/ccs3.70123
UR - https://europepmc.org/article/MED/42953376
AB - Claudin-4 (CLDN4), a key tight junction protein, has been implicated in tumor progression; however, its functional role and regulatory mechanisms in thyroid cancer remain unclear. This study aimed to investigate the contribution of CLDN4 to malignant progression and its interaction with the tumor-immune microenvironment. Single-cell and bulk transcriptomic data were integrated to identify CLDN4-associated malignant epithelial subpopulations. CLDN4 expression was validated in 25 paired papillary thyroid carcinoma (PTC) tissues by qRT-PCR, western blotting, and immunohistochemistry. Functional assays were performed using CLDN4-overexpressing and CLDN4-knockdown B-CPAP and TPC-1 cells. The miR-941-CLDN4 interaction was verified by luciferase reporter assays. PI3K/AKT signaling and macrophage polarization were evaluated in vitro, and tumor growth was assessed in a xenograft mouse model. A CLDN4-high epithelial subpopulation was identified and associated with advanced tumor stage and PI3K/AKT activation. CLDN4 was upregulated in PTC tissues, whereas miR-941 was downregulated. High CLDN4 expression correlated with larger tumor size, lymphatic metastasis, and vascular migration. CLDN4 overexpression promoted proliferation, migration, colony formation, and apoptosis resistance, whereas knockdown produced the opposite effects. miR-941 directly targeted CLDN4 and attenuated its oncogenic effects. CLDN4 activated PI3K/AKT signaling, while PI3K inhibition reversed these phenotypes. CLDN4 also promoted M2 macrophage polarization and suppressed M1 polarization. In vivo, CLDN4 enhanced tumor growth, which was inhibited by PI3K blockade. miR-941 suppresses CLDN4 to inhibit PTC progression through modulation of the PI3K/AKT pathway. These findings provide mechanistic insights into tumor progression and immune microenvironment remodeling, highlighting CLDN4 as a potential therapeutic target.
SN - 1873-9601
SN - 1873-961X
ER -